In Brief: Graham-Field
This article was originally published in The Gray Sheet
Graham-Field: Durable medical equipment manufacturer/distributor completes proposed acquisition of Fuqua Enterprises, the company reports Dec. 31. Under terms of the deal, announced on Sept. 5 ("The Gray Sheet" Sept. 15, I&W-6) and revised on Sept. 29, Fuqua receives 2.1 mil. shares of Graham-Field common stock in a tax-free exchange for each common share of Fuqua, which prior to completion of the merger had approximately 4.5 mil. shares outstanding. As part of the deal, Graham-Field gains Irving Tanning Company, a $135 mil. Fuqua subsidiary, which Graham-Field says "does not fit into the long-term strategic business plans" of the company and will be treated as an asset held for sale...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.